Showing results (51-60 of 302) with videos related to

Sort By:
Pageof 31
Experimental Hematology & Oncology|March 21, 2023
PD-L1+ macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphomaRaphael E Steiner, Edwin R Parra, Francisco Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin LymphomaPaolo Strati, Lei Feng, Andrey Tyshevich, et al.
Leukemia & Lymphoma|March 9, 2023
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacyAjlan Al Zaki, Dustin McCurry, Paolo Strati
British Journal of Clinical Pharmacology|May 29, 2020
Chimeric antigen receptor T-cell therapy toxicitiesUri Greenbaum, Partow Kebriaei, Samer A Srour, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 26, 2025
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell LymphomaTony Z Zhuang, Chen Zhang, Paolo Strati
The Journal of Clinical Investigation|July 26, 2022
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responsesGabrielle Romain, Paolo Strati, Ali Rezvan, et al.
British Journal of Haematology|September 25, 2009
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitorsAnnunziata Gloghini, Daniela Buglio, Noor M Khaskhely, et al.
Haematologica|November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomaRaphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
Nature Communications|August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trialPaolo Strati, Lei Feng, Jason R Westin, et al.
Blood Advances|January 11, 2022
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapyAjlan Al Zaki, Lei Feng, Grace Watson, et al.
Pageof 31